Université Libre de Bruxelles - Hôpital Erasme

The Université Libre de Bruxelles - Hôpital Erasme Gastroenterology Department conducts extensive research on inflammatory bowel disease, including Crohn's disease and ulcerative colitis, as well as liver disorders such as non‑alcoholic steatohepatitis. Trials aim to test novel biologics, improve endoscopic outcomes, and refine diagnostic tools to enhance patient quality of life.

• Evaluation of new biologic agents for moderate to severe IBD
• Investigating non‑invasive biomarkers for liver fibrosis
• Assessing long‑term safety of emerging therapies for NASH

With 245 active studies and 14 investigators, the site integrates endoscopy, imaging, and translational science to advance gastrointestinal care across Europe.

Research focuses on cholangiocarcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma. Clinical trials evaluate targeted therapies, adjuvant immunotherapy, and combination regimens to improve survival and reduce recurrence after surgery.

• Adjuvant immunotherapy after resection of HCC
• Targeted agents for advanced biliary tract cancer
• Combination chemotherapy with radiotherapy for borderline resectable pancreatic cancer

The multidisciplinary approach leverages the hospital’s surgical expertise and translational oncology platform, supporting personalized treatment strategies.

The site addresses atherosclerotic cardiovascular disease, atrial fibrillation, and metabolic conditions such as type 2 diabetes and obesity. Trials aim to evaluate anticoagulants, lipid‑lowering agents, and lifestyle interventions to prevent cardiovascular events and improve metabolic health.

• Comparing novel anticoagulants for stroke prevention in AF
• Testing lipid‑lowering therapies targeting elevated lipoprotein(a)
• Assessing weight‑loss drugs for obesity without diabetes

Leveraging a strong cardiology network, the department contributes to guideline‑shaping studies with robust patient enrollment.

Investigations target pulmonary arterial hypertension, chronic obstructive pulmonary disease, and emerging infections like COVID‑19. Studies evaluate vasodilators, anti‑inflammatory inhaled agents, and supportive therapies to enhance lung function and reduce morbidity.

• Oral FXIa inhibitor for stroke prevention in PAH patients
• Inhaled molgramostim for autoimmune pulmonary alveolar proteinosis
• Long‑term safety of inhaled treprostinil in fibrotic lung disease

The department collaborates with pulmonary specialists and intensive care units, ensuring comprehensive assessment of respiratory outcomes.

Trials encompass autoimmune conditions such as systemic lupus erythematosus, psoriatic arthritis, hidradenitis suppurativa, and rare diseases like autoimmune pulmonary alveolar proteinosis. Objectives include testing targeted immunomodulators, improving disease activity scores, and establishing safety profiles.

• Upadacitinib versus placebo in SLE
• Filgotinib for axial spondyloarthritis
• Povorcitinib for moderate to severe hidradenitis suppurativa

With a focus on patient‑reported outcomes, the research integrates rheumatology and dermatology expertise to advance therapeutic options.

The program investigates neurodegenerative and psychiatric illnesses, including multiple sclerosis, major depressive disorder, and post‑traumatic stress disorder. Studies assess novel oral agents, reconsolidation therapies, and neuroprotective strategies to improve cognition and mood.

• Evaluating oral FXIa inhibitor for stroke prevention in MS patients
• Aticaprant as adjunctive therapy for MDD with anhedonia
• Reconsolidation therapy versus prolonged exposure for PTSD

Multidisciplinary collaboration with neurology, psychiatry, and imaging units supports innovative approaches to brain health.